Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.60 |
| ▸ | MMP1 | P03956 | 13/20 | 0.60 |
| ▸ | MMP9 | P14780 | 6/20 | 0.60 |
| ▸ | MMP2 | P08253 | 11/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 3/20 | 0.49 |
| ▸ | MMP14 | P50281 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | MMP12 | P39900 | 2/20 | 0.49 |
| ▸ | MMP16 | P51512 | 2/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210477 | 0.91 | MMP1 (0.57) | MMP13MMP1MMP9MMP2MMP8 | |
| SCHEMBL7210446 | 0.87 | MMP13 (0.50) | MMP13MMP1MMP9MMP2PDE4A | |
| SCHEMBL7210912 | 0.85 | MMP1 (0.51) | MMP13MMP1MMP9MMP2 | |
| SCHEMBL7212002 | 0.84 | NPC1 (0.51) | MMP13MMP1MMP9MMP2PDE4A | |
| SCHEMBL7210980 | 0.83 | MMP13 (0.52) | MMP13MMP1MMP9MMP2 | |
| SCHEMBL7212125 | 0.80 | MMP13 (0.50) | MMP13MMP1MMP9MMP2 | |
| SCHEMBL7210461 | 0.80 | MMP13 (0.54) | MMP13MMP1MMP9MMP2MMP3 | |
| SCHEMBL6774922 | 0.80 | MMP13 (0.67) | MMP13MMP1MMP2MMP14MEP1B | |
| SCHEMBL7210895 | 0.79 | MMP9 (0.43) | MMP13MMP1MMP9MMP2PDE4A | |
| SCHEMBL7215391 | 0.79 | ALDH1A1 (0.55) | MMP13MMP1MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2003-09-04 | — | — | US | claimed |
| EP-1037868-B1 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2003-02-05 | — | — | EP | claimed |
| EP-1037868-A2 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999026909-A2 | ALPHA-HYDROXY, -AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-03 | — | — | WO | claimed |
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1037868-B1 | $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6437177-B1 | DISEASES INVOLVING CONNECTIVE TISSUE DEGRADATION; ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, DERMAL, OR GASTRIC ULCERATION, AND ASTHMA; 2-HYDROXY-2-(PHENYLTHIO) METHYL-3-(4-BUTOXYBENZENESULFONYL)PROPIONIC ACID | PHARMACIA & UPJOHN COMPANY | 2002-08-20 | — | — | US | disclosed |
| WO-2001038301-A1 | (R)-3-(4-CHLOROBIPHENYL-SULFONYL)-2-HYDROXY-2-(PHENYLTHIO)METHYLPROPIONIC ACID AND ITS USE MATRIX METALLOPROTEINASE | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166687-A1 | ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | MMP1, MMP8, HRH3 | MMP13 5/4885MMP1 1/4885MMP9 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.